Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas
Status:
Not yet recruiting
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
A multi-institutional open-label phase 1/2 trial of selumetinib in combination with AZD5153
and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will
be separated in two parts and will be open to all patients with refractory/relapsed sarcomas.
The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.